X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BXCL501 (dexmedetomidine HCl) is an adrenergic receptor alpha-2 agonist, small molecule drug candidate, which is currently being evaluated for the treatment of agitation associated With alzheimer’s dementia.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: Igalmi
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 10, 2024
Details:
The Company intends to use the net proceeds to fund planned clinical trials of BXCL501 (sublingual dexmedetomidine), being evaluated for the treatment of Opioid Use Disorder.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BXCL501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $25.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering March 25, 2024
Details:
Through termination. the company intends to focus on the commercialization of Igalmi (dexmedetomidine). It is approved by the FDA for the treatment of acute treatment of agitation associated with schizophrenia and associated bipolar I or II disorder.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Igalmi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Termination February 13, 2024
Details:
BXCL701 (talabostat mesylate) is an investigational, oral small molecule inhibitor of a class of enzymes called DPPs, specifically DPP8/9 and DPP4. It is being evaluated for treatment of small cell neuroendocrine prostate cancer.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 12, 2024
Details:
The company intends to use the net proceeds to fund ongoing clinical trials and commercialization of its approved product, including Igalmi (dexmedetomidine), indicated for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: Igalmi
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $60.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering February 08, 2024
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator. It is being evaluated in phase 2 clinial trials in combination with Keytruda (pembrolizumab) for the treatment of metastatic pancreatic ductal adenocarcinoma.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 06, 2024
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with mCRPC of Adenocarcinoma Phenotype.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2023
Details:
BXCL501 (sublingual dexmedetomidine) is a selective alpha-2 adrenergic receptor agonist, which is investigated for the treatment of Opioid Use Disorder.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Psychiatry/Psychology Product Name: BXCL501
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
BXCL501 is an investigational proprietary, orally dissolving film formulation of dexmedetomidine, a selective alpha-2 adrenergic receptor agonist and potentially targets an important mediator of Alzheimer’s Disease-Related Agitation.
Lead Product(s): Dexmedetomidine Hydrochloride
Therapeutic Area: Neurology Product Name: BXCL501
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 25, 2023
Details:
BXCL701 (talabostat mesylate) is an investigational, oral innate immune activator designed to initiate inflammation in the tumor microenvironment. it is currently being developed for combination with (pembrolizumab) in patients with small cell neuroendocrine prostate cancer.
Lead Product(s): Talabostat Mesylate,Pembrolizumab
Therapeutic Area: Oncology Product Name: BXCL701
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
